Evolving an antibody: innovation in therapeutic antibody design
Michael Weiner (left) is a member of the BioTechniques Editorial Board and the founder of AbbraTech (CT, USA), a new company focused on the generation of antibodies for therapeutic applications. We caught up with Michael at this year’s annual meeting of the American Association for Cancer Research (5-10 April, 2024; San Diego, CA, USA), to discuss his novel approach to antibody development, the current sticking points in the field of antibody therapeutics and the innovative approaches that are being used to overcome them. Can you tell us more about AbbraTech's technologies and focuses? Of course! Instead of conducting typical antibody...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
